These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 23750489)

  • 1. Risk of oral antifungal agent-induced liver injury in Taiwanese.
    Kao WY; Su CW; Huang YS; Chou YC; Chen YC; Chung WH; Hou MC; Lin HC; Lee FY; Wu JC
    Br J Clin Pharmacol; 2014 Jan; 77(1):180-9. PubMed ID: 23750489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A cohort study on the risk of acute liver injury among users of ketoconazole and other antifungal drugs.
    García Rodríguez LA; Duque A; Castellsague J; Pérez-Gutthann S; Stricker BH
    Br J Clin Pharmacol; 1999 Dec; 48(6):847-52. PubMed ID: 10594489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of itraconazole, terbinafine, fluconazole, griseofulvin and ketoconazole in the treatment of Scopulariopsis brevicaulis causing onychomycosis of the toes.
    Gupta AK; Gregurek-Novak T
    Dermatology; 2001; 202(3):235-8. PubMed ID: 11385230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A risk-benefit assessment of the newer oral antifungal agents used to treat onychomycosis.
    Gupta AK; Shear NH
    Drug Saf; 2000 Jan; 22(1):33-52. PubMed ID: 10647975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic antifungal therapy for tinea capitis in children.
    Chen X; Jiang X; Yang M; González U; Lin X; Hua X; Xue S; Zhang M; Bennett C
    Cochrane Database Syst Rev; 2016 May; 2016(5):CD004685. PubMed ID: 27169520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral Azole Antifungal Medications and Risk of Acute Liver Injury, Overall and by Chronic Liver Disease Status.
    Lo Re V; Carbonari DM; Lewis JD; Forde KA; Goldberg DS; Reddy KR; Haynes K; Roy JA; Sha D; Marks AR; Schneider JL; Strom BL; Corley DA
    Am J Med; 2016 Mar; 129(3):283-91.e5. PubMed ID: 26597673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacoeconomic analysis of ciclopirox nail lacquer solution 8% and the new oral antifungal agents used to treat dermatophyte toe onychomycosis in the United States.
    Gupta AK
    J Am Acad Dermatol; 2000 Oct; 43(4 Suppl):S81-95. PubMed ID: 11051137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Hepatotoxicity of Fluconazole, Ketoconazole, Itraconazole, Terbinafine, and Griseofulvin in Rats.
    Khoza S; Moyo I; Ncube D
    J Toxicol; 2017; 2017():6746989. PubMed ID: 28261269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The new oral antifungal agents for onychomycosis of the toenails.
    Gupta AK; Shear NH
    J Eur Acad Dermatol Venereol; 1999 Jul; 13(1):1-13. PubMed ID: 10565624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic optimisation of oral antifungal therapy.
    Schäfer-Korting M
    Clin Pharmacokinet; 1993 Oct; 25(4):329-41. PubMed ID: 8261715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liver injury associated with ketoconazole: review of the published evidence.
    Greenblatt HK; Greenblatt DJ
    J Clin Pharmacol; 2014 Dec; 54(12):1321-9. PubMed ID: 25216238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of oral antifungal agents to treat onychomycosis.
    Gupta AK; Ryder JE
    Dermatol Clin; 2003 Jul; 21(3):469-79, vi. PubMed ID: 12956199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacoeconomic analysis of oral antifungal therapies used to treat dermatophyte onychomycosis of the toenails. A US analysis.
    Gupta AK
    Pharmacoeconomics; 1998 Feb; 13(2):243-56. PubMed ID: 10178650
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Singh SK; Patwa DK; Tilak R; Das A; Singh TB
    Indian J Dermatol Venereol Leprol; 2019; 85(4):388-392. PubMed ID: 30950409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral antifungal medication for toenail onychomycosis.
    Kreijkamp-Kaspers S; Hawke K; Guo L; Kerin G; Bell-Syer SE; Magin P; Bell-Syer SV; van Driel ML
    Cochrane Database Syst Rev; 2017 Jul; 7(7):CD010031. PubMed ID: 28707751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral antifungal-exacerbated inflammatory flare-up reactions of dermatomycosis : case reports and review of the literature.
    Nikkels AF; Nikkels-Tassoudji N; Piérard GE
    Am J Clin Dermatol; 2006; 7(5):327-31. PubMed ID: 17007544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk/benefit ratio of modern antifungal therapy: focus on hepatic reactions.
    Hay RJ
    J Am Acad Dermatol; 1993 Jul; 29(1):S50-4. PubMed ID: 8315062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Limited effectiveness of four oral antifungal drugs (fluconazole, griseofulvin, itraconazole and terbinafine) in the current epidemic of altered dermatophytosis in India: results of a randomized pragmatic trial.
    Singh S; Chandra U; Anchan VN; Verma P; Tilak R
    Br J Dermatol; 2020 Nov; 183(5):840-846. PubMed ID: 32538466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Oral treatment of onychomycosis of the toe nails; comparison of cost-effectiveness of griseofulvin, itraconazole, ketoconazole and terbinafine].
    Bergman W; Rutten FF
    Ned Tijdschr Geneeskd; 1994 Nov; 138(47):2346-50. PubMed ID: 7969635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An evaluation of intermittent therapies used to treat onychomycosis and other dermatomycoses with the oral antifungal agents.
    Gupta AK; Del Rosso JQ
    Int J Dermatol; 2000 Jun; 39(6):401-11. PubMed ID: 10944084
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.